Exelixis (EXEL) Other Working Capital Changes (2010 - 2026)
Exelixis' (EXEL) quarterly Other Working Capital Changes came in at $162000.0 in Q2 2023, up 124.47% year-on-year from $72169.6 in Q2 2022, and up 122.91% quarter-over-quarter from -$707000.0 in Q1 2023.
Exelixis (EXEL) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Exelixis' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $162000.0 for Q2 2023.
- On a quarterly basis, Other Working Capital Changes rose 124.47% year-over-year to $162000.0 in Q2 2023; TTM through Jun 2023 was -$1.2 million, a 608.28% decrease from a year earlier, with the FY2023 full-year figure at -$3.1 million, down 26.46% from the prior year.
- Other Working Capital Changes climbed to $162000.0 in Q2 2023 per EXEL's latest filing, from -$707000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $104.7 million in Q3 2025 and bottomed at -$94.1 million in Q1 2025.
- The 5-year median for Other Working Capital Changes is $1.8 million (2023), against an average of $6.0 million.
- Across the five-year window, Other Working Capital Changes jumped 774.03% in 2020 and slumped 162.21% in 2022, its largest moves.
- Year by year, Other Working Capital Changes stood at -$1.1 million in 2019, then soared by 931.77% to $8.8 million in 2020, then slumped by 104.81% to -$426000.0 in 2021, then soared by 251.88% to $647000.0 in 2022, then plunged by 74.96% to $162000.0 in 2023.
- Per Business Quant, the three latest EXEL Other Working Capital Changes figures stand at $162000.0 (Q2 2023), -$707000.0 (Q1 2023), and $647000.0 (Q4 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -58.65 Mn |
| Apr 3, 2026 | -58.65 Mn |
| Apr 3, 2026 | -58.65 Mn |
| Jan 2, 2026 | 97.03 Mn |
| Jan 2, 2026 | 97.03 Mn |
| Jan 2, 2026 | 97.03 Mn |
| Oct 3, 2025 | -47.65 Mn |
| Oct 3, 2025 | -47.65 Mn |
| Oct 3, 2025 | -47.65 Mn |
| Jul 4, 2025 | 104.71 Mn |
| Jul 4, 2025 | 104.71 Mn |
| Jul 4, 2025 | 104.71 Mn |
| Apr 4, 2025 | -20.32 Mn |
| Apr 4, 2025 | -20.32 Mn |
| Apr 4, 2025 | -20.32 Mn |
| Jan 3, 2025 | -94.15 Mn |
| Jan 3, 2025 | -94.15 Mn |
| Jan 3, 2025 | -94.15 Mn |
| Sep 27, 2024 | 96.73 Mn |
| Sep 27, 2024 | 96.73 Mn |